180 Life Sciences Equity Warrant Exp 7th Nov 2025 ATNFW:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 8:27 AM EDT
0.01quote price arrow down-0.0003 (-3.6145%)
Volume
12,055
Close
0.0083quote price arrow down-0.0008 (-8.7812%)
Volume
10,840
52 week range
0.00 - 0.02
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0083
  • 52 Week High0.02
  • 52 Week High Date08/17/23
  • 52 Week Low0.00
  • 52 Week Low Date03/13/24

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0083
  • 52 Week High0.02
  • 52 Week High Date08/17/23
  • 52 Week Low0.00
  • 52 Week Low Date03/13/24
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On 180 Life Sciences Equity Warrant Exp 7th Nov 2025

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor...
Blair Jordan
Interim Chief Executive Officer, Director
Ozan Pamir
Chief Financial Officer, Company Secretary
Address
3000 El Camino Real, Bldg 4, Ste 200
Palo Alto, CA
94306
United States